Vir Biotechnology Inc V.VIR

Primary Symbol: VIR

Healthcare Biotechnology

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

NDAQ:VIR - Post by User

Vir Biotechnology Inc > Made an Entry Here

<< Previous

Bullboard Posts

Next >>

Comment by tsxventurewatchon Jan 06, 2021 3:42am

179 Views

Post# 32230822

RE:RE:Made an Entry Here

It traded at those heights during boom times in the cannabis sector. What's interesting is that the company is now in the best position it has ever been yet trades at a C$10 Million market cap and is way under the radar - you barely see any discussion on the company across all platforms. Let's see what 2021 brings forth

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario